RecruitingPhase 2NCT07169279
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Studying Achondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- QED Therapeutics, a BridgeBio company
- Intervention
- Infigratinib is provided as a single dose of minitablets for oral administration(drug)
- Enrollment
- 77 enrolled
- Eligibility
- 0 years · All sexes
- Timeline
- 2025 – 2032
Study locations (13)
- UCSF Benioff Children's Hospital, Oakland, California, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison, Wisconsin, United States
- Murdoch Children's Research Institute, Parkville, Victoria, Australia
- Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
- Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
- Paediatric Clinical Research Unit at Oslo University Hospital, Oslo, Norway
- KK Women's and Children's Hospital, Singapore, Singapore
- Unidad de Cirugia Artroscopica (UCA), Vitoria-Gasteiz, Spain
- NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
- Guy's and Saint Thomas' NHS Foundation Trust, London, United Kingdom
- Manchester University NHS Foundation Trust, Manchester, United Kingdom
- Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07169279 on ClinicalTrials.govOther trials for Achondroplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07388966Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaSYSNAV
- RECRUITINGPHASE2, PHASE3NCT07441876A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaBioMarin Pharmaceutical
- RECRUITINGNCT07301463A Study in Children With AchondroplasiaAbbisko Therapeutics Co, Ltd
- RECRUITINGPHASE2NCT06842355A Study of TYRA-300 in Children With Achondroplasia: BEACH301Tyra Biosciences, Inc
- RECRUITINGPHASE2NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S
- RECRUITINGPHASE3NCT06926491Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）Kyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE2NCT06433557A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S
- RECRUITINGPHASE2NCT06079398A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaAscendis Pharma A/S